methylergonovine has been researched along with Cardiac Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aalikhani, M; Alikhani, M; Bazi, Z; Oladnabi, M; Shamsabadi, F | 1 |
| Bonnet, JL; Bory, M; Canavy, I; Dutrillat, C; Garcia, E | 1 |
2 other study(ies) available for methylergonovine and Cardiac Diseases
| Article | Year |
|---|---|
In silico drug repurposing for the treatment of heart diseases using gene expression data and molecular docking techniques.
Topics: Aminoisobutyric Acids; Aminopterin; Bridged Bicyclo Compounds, Heterocyclic; Cyclopropanes; Daunorubicin; Digoxin; Drug Repositioning; Gene Expression; Heart Diseases; Humans; Lactams, Macrocyclic; Leucine; Ligands; Methylergonovine; Molecular Docking Simulation; Morpholines; Proline; Quinoxalines; Sulfonamides | 2021 |
[Prospective study on the mechanism of myocardial infarction without significant coronary stenosis].
Topics: Adult; Aged; Arteriosclerosis; Blood Coagulation Disorders; Blood Coagulation Tests; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Thrombosis; Coronary Vasospasm; Echocardiography; Female; Heart Diseases; Humans; Male; Methylergonovine; Middle Aged; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Prospective Studies; Risk Factors; Thrombocythemia, Essential; Thrombosis; Vasoconstrictor Agents | 1999 |